Dare Bioscience, INC. (DARE) — SEC Filings

Overview

Dare Bioscience, INC. (DARE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a QUALIF filed on Apr 2, 2026: Dare Bioscience, Inc. filed a Notice of Qualification (Form QUALIF) on April 1, 2026, under Regulation A. The filing indicates the company's qualification for a specific offering, with its principal business in Pharmaceutical Preparations.

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 39 neutral. The dominant filing sentiment for Dare Bioscience, INC. is neutral.

Filing Type Overview

Dare Bioscience, INC. (DARE) has filed 32 8-K, 1 QUALIF, 6 10-Q, 1 DEFA14A, 2 DEF 14A, 2 10-K, 1 S-1 with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• 8-K Filing — 8-K · Apr 22, 2026
• Dare Bioscience Files Notice of Qualification — QUALIF · Apr 2, 2026 Risk: medium
  Dare Bioscience, Inc. filed a Notice of Qualification (Form QUALIF) on April 1, 2026, under Regulation A. The filing indicates the company's qualification for a
• 8-K Filing — 8-K · Dec 1, 2025
• Dare Bioscience Files 8-K on Financials — 8-K · Nov 13, 2025 Risk: low
  On November 13, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Dare Bioscience Shifts Strategy Amidst Widening Losses, Boosts Cash Reserves — 10-Q · Nov 13, 2025 Risk: high
  Dare Bioscience, Inc. reported a net loss of $3.56 million for the three months ended September 30, 2025, a decrease from the $4.70 million net loss in the same
• Dare Bioscience (DARE) Files 8-K Report — 8-K · Sep 2, 2025 Risk: low
  On September 2, 2025, Dare Bioscience, Inc. (DARE) filed an 8-K report. The filing indicates that the company's common stock is registered on the Nasdaq Capital
• Dare Bioscience, Inc. Files 8-K Report — 8-K · Aug 14, 2025 Risk: low
  On August 14, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 3655 Nobel Drive, S
• Dare Bioscience's Q2 Loss Widens Amid Strategy Shift, Cash Drains — 10-Q · Aug 14, 2025 Risk: high
  Dare Bioscience, Inc. reported a significant net loss of $8,394,790 for the six months ended June 30, 2025, a stark contrast to the net income of $6,155,300 rep
• Dare Bioscience Files 8-K Report — 8-K · Jul 25, 2025 Risk: low
  On July 25, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transa
• Dare Bioscience Files 8-K for Unspecified Event — 8-K · Jul 21, 2025 Risk: medium
  On July 18, 2025, Dare Bioscience, Inc. filed an 8-K report detailing an 'Other Event'. The filing does not provide specific details about the event itself, but
• Dare Bioscience Files 8-K Report — 8-K · Jul 14, 2025 Risk: low
  On July 14, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regu
• Dare Bioscience Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Jul 9, 2025 Risk: medium
  On July 9, 2025, Dare Bioscience, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of a ne
• Dare Bioscience Files 8-K: Other Events — 8-K · Jun 25, 2025 Risk: low
  On June 25, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transa
• Dare Bioscience Files Proxy Materials — DEFA14A · Jun 12, 2025 Risk: low
  Dare Bioscience, Inc. filed a Definitive Additional Materials (DEFA14A) on June 12, 2025. This filing relates to materials provided to shareholders, likely conc
• 8-K Filing — 8-K · Jun 9, 2025
• Dare Bioscience Files 8-K on Financials — 8-K · May 13, 2025 Risk: low
  On May 13, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well a
• Dare Bioscience Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Dare Bioscience, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuti
• Dare Bioscience Executive Compensation Revealed — DEF 14A · Apr 24, 2025 Risk: medium
  Dare Bioscience, Inc. filed its DEF 14A on April 24, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes in
• Dare Bioscience Files 8-K for Other Event — 8-K · Apr 11, 2025 Risk: medium
  On April 11, 2025, Dare Bioscience, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, bu
• Dare Bioscience Files 8-K on Financials — 8-K · Mar 31, 2025 Risk: low
  Dare Bioscience, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition. The filing includes financial statements a
• 10-K Filing — 10-K · Mar 31, 2025
• Dare Bioscience Faces Nasdaq Delisting Risk — 8-K · Feb 14, 2025 Risk: medium
  On February 13, 2025, Dare Bioscience, Inc. filed an 8-K report indicating a potential delisting from the Nasdaq Capital Market. The company received a deficien
• Dare Bioscience Files 8-K: Reg FD & Financials — 8-K · Feb 10, 2025 Risk: low
  On February 10, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. T
• 8-K Filing — 8-K · Jan 13, 2025
• Dare Bioscience Files 8-K Report — 8-K · Dec 16, 2024 Risk: low
  On December 16, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
• Dare Bioscience Files S-1 for New Securities Offering — S-1 · Nov 15, 2024 Risk: medium
  Dare Bioscience, Inc. filed an S-1 registration statement on November 15, 2024, to register securities under the Securities Act of 1933. The company, formerly k
• Dare Bioscience Files 8-K on Financials — 8-K · Nov 14, 2024 Risk: medium
  On November 14, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, with
• Dare Bioscience Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Dare Bioscience, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc
• 8-K Filing — 8-K · Oct 25, 2024
• Dare Bioscience Files 8-K with Material Agreement Details — 8-K · Oct 23, 2024 Risk: medium
  On October 23, 2024, Dare Bioscience, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and
• Dare Bioscience Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 21, 2024 Risk: medium
  On October 21, 2024, Dare Bioscience, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and
• Dare Bioscience Files 8-K on Financials — 8-K · Aug 12, 2024 Risk: low
  On August 12, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along
• Dare Bioscience Files Q2 2024 10-Q Report — 10-Q · Aug 12, 2024 Risk: medium
  Dare Bioscience, Inc. filed its quarterly report for the period ended June 30, 2024. The company is incorporated in Delaware and its principal executive offices
• Dare Bioscience Closes $15M Public Offering — 8-K · Jul 19, 2024 Risk: medium
  On July 18, 2024, Dare Bioscience, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised approxim
• Dare Bioscience Secures $50M Financing from OrbiMed — 8-K · Jun 27, 2024 Risk: medium
  On June 21, 2024, Dare Bioscience, Inc. announced a strategic financing agreement with OrbiMed, a leading healthcare investment firm. The agreement includes a $
• Dare Bioscience Holds Annual Stockholder Meeting — 8-K · Jun 7, 2024 Risk: low
  On June 5, 2024, Dare Bioscience, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders voted on se
• Dare Bioscience Files 8-K on Financials — 8-K · May 14, 2024 Risk: low
  On May 14, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well a
• 10-Q Filing — 10-Q · May 14, 2024
• Dare Bioscience Enters Material Agreement, Faces Financial Obligation — 8-K · Apr 30, 2024 Risk: medium
  On April 29, 2024, Dare Bioscience, Inc. entered into a material definitive agreement related to the completion of an acquisition or disposition of assets. This
• Dare Bioscience Announces 2024 Annual Meeting of Stockholders on June 5 — DEF 14A · Apr 26, 2024 Risk: medium
  Dare Bioscience, Inc. (DARE) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Dare Bioscience, Inc.
• Dare Bioscience Files 8-K on Financials — 8-K · Mar 28, 2024 Risk: low
  On March 28, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, includi
• Dare Bioscience, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  Dare Bioscience, Inc. (DARE) filed a Annual Report (10-K) with the SEC on March 28, 2024. Dare Bioscience, Inc. filed its 2023 Form 10-K on March 28, 2024. The
• Dare Bioscience Files Routine 8-K on Jan 26, 2024 — 8-K · Jan 26, 2024
  Dare Bioscience, Inc. filed an 8-K on January 26, 2024, reporting an event that occurred on January 23, 2024. This filing is a standard current report, indicati
• Dare Bioscience Faces Nasdaq Delisting Risk Over Bid Price — 8-K · Jan 19, 2024
  Dare Bioscience, Inc. (DARE) reported on January 17, 2024, that it received a notice from Nasdaq regarding its failure to meet the minimum bid price requirement
• Dare Bioscience Files 8-K: Regulation FD Disclosure & Exhibits — 8-K · Jan 8, 2024
  Dare Bioscience, Inc. filed an 8-K on January 8, 2024, indicating a Regulation FD Disclosure and the filing of Financial Statements and Exhibits. This filing, u

Risk Profile

Risk Assessment: Of DARE's 35 recent filings, 2 were flagged as high-risk, 18 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Dare Bioscience, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $2,262
• Net Income: $-3,562,766
• EPS: N/A
• Debt-to-Equity: 9.76
• Cash Position: $23,075,261
• Operating Margin: N/A
• Total Assets: $30,748,574
• Total Debt: $27,890,671

Key Executives

• Sabrina Martucci Johnson

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Dare Bioscience often rely on external funding and strategic partnerships to advance their pipelines. The trend towards diversifying revenue streams through earlier market access products (like compounding and consumer health) reflects a broader industry effort to mitigate the risks associated with lengthy FDA approval processes.

Top Tags

filing (6) · 8-k (6) · financial-condition (5) · corporate-governance (5) · sec-filing (4) · pharmaceuticals (3) · results-of-operations (3) · regulatory (3) · disclosure (3) · 10-Q (3)

Key Numbers

• Qualification Date: 2026-04-01 — Date of qualification for the offering
• File Number: 024-12688 — Associated with the Regulation A filing
• Cash and cash equivalents: $23.08M — Increased from $15.70M at Dec 31, 2024, primarily due to equity issuance.
• Net loss for nine months: $11.96M — Compared to $1.45M net income in the prior year, reflecting a significant decline.
• Total revenue for Q3 2025: $2,262 — Down 94.5% from $41,691 in Q3 2024.
• Research and development expenses for nine months: $4.90M — Decreased by 55.3% from $10.97M in the prior year, indicating a strategic shift.
• Net proceeds from common stock issuance: $19.66M — Primary source of cash increase for the nine months ended September 30, 2025.
• Accumulated deficit: $187.25M — Reflects historical unprofitability and ongoing losses.
• Shares outstanding: 13,929,502 — As of September 30, 2025, significantly increased from 8,700,386 at Dec 31, 2024 due to equity issuance.
• Commission File Number: 001-36395 — Identifier for Dare Bioscience, Inc.
• I.R.S. Employer Identification No.: 20-4139823 — Tax identification for Dare Bioscience, Inc.
• Net Loss: $8,394,790 — For the six months ended June 30, 2025, compared to $6,155,300 net income in 2024.
• Cash and Cash Equivalents: $5,035,006 — As of June 30, 2025, down from $15,698,174 at December 31, 2024.
• Total Revenue: $4,255 — For the six months ended June 30, 2025, an 86.6% decrease from $31,740 in 2024.
• Total Operating Expenses: $8,413,173 — For the six months ended June 30, 2025, a 37.3% decrease from $13,413,679 in 2024.

Related Companies

XOMA · OGN · DAR · DBIO

Frequently Asked Questions